Although less than 2% of primary breast tumors contain activating Ras mutations [27,28], the Her2 oncoprotein signals through Ras [27,29], and Her2 mutation or amplification occur in ~25–30% of all breast cancers [30,31]. This evidence concerns the gene ERBB2 and breast cancer.